StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

5-Amino-4-oxovaleriansure

5-Aminolevulinic Acid

HCID 137
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
106-60-5
Standard-SMILES
NCC(=O)CCC(=O)O
InChIKey
ZGXJTSGNIOSYLO-UHFFFAOYSA-N
Summenformel
C5H9NO3
Durchschnittliche Molmasse
131,13 g/mol
Monoisotopische Masse
131,05824315

Überblick

5-aminolevulinic acid is the simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. It has a role as an antineoplastic agent, a photosensitizing agent, a dermatologic drug, a prodrug, a mouse metabolite, a Saccharomyces cerevisiae metabolite, a plant metabolite, an Escherichia coli metabolite and a human metabolite. It is a delta-amino acid and a 4-oxo monocarboxylic acid. It is functionally related to a 4-oxopentanoic acid. It is a conjugate base of a 5-ammoniolevulinic acid. It is a conjugate acid of a 5-aminolevulinate. It is a tautomer of a 5-ammoniolevulinate.

Namen und Bezeichner

Bevorzugter Name
5-Aminolevulinic Acid
IUPAC
5-amino-4-oxopentanoic acid
Lokaler Name
5-Amino-4-oxovaleriansure
Englischer Name
5-Aminolevulinic acid
Summenformel
C5H9NO3
Molmasse
131.13

Namen und Synonyme

5-Aminolevulinic acidAminolevulinic acid106-60-55-Amino-4-oxopentanoic acid5-Aminolevulinatedelta-aminolevulinic acid5-ALA5-amino-4-oxo-pentanoic aciddelta-ALA5-amino-levulinate5-amino-levulinic acid5-Amino-4-oxopentanoate
Weitere Namen anzeigen
5-AMINOLAEVULINIC ACID5-amino-4-oxovaleric acid5-AMinelevulic acid (5-ALA)4-Oxo-5-aminopentanoic acidKerastickAminolevulinateaminolevulinicacid5-aminolevulinicaci5-Aminobutyric acid
Amino-levulinic aciddelta-aminolevulinate4-oxo-5-amino-pentanoic acid88755TAZ87DTXSID8048490CHEBI:17549CHEBI:121095-amino levulinic acid

Datenbank-Bezeichner

CAS
106-60-5
PubChem CID
137
DTXSID

Eigenschaften

Berechnete Struktureigenschaften

XLogP
-3,8
Polarare Oberfläche (TPSA)
80,4 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
4
Frei drehbare Bindungen
4
Schwere Atome
9
Formalladung
0
Komplexität
121

Experimentelle und physikochemische Eigenschaften

DrugsPharmaceuticals -> Listed in ZINC15
LipidsFatty Acyls [FA] -> Fatty Acids and Conjugates [FA01] -> Amino fatty acids [FA0110]
Solubility · 3 Einträge

Very soluble

1000 mg/mL at 25 °C

18.6 [ug/mL] (The mean of the results at pH 7.4)

Human DrugsBreast Feeding; Lactation; Milk, Human; Dermatologic Agents; Photosensitizing Agents
Melting Point · 2 Einträge

156-158 °C

156 - 158 °C

Physical DescriptionSolid
Collision Cross Section · 2 Einträge

130.7 Ų [M+H]+ [CCS Type: DT; Method: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]

130.7 Ų [M+H]+

Physikochemische Eigenschaften

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Warning

H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 2 reports by companies from 1 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxikologische Informationen

Exposure RoutesOral bioavailability is 50-60%.
Toxicity Summary · 1 Eintrag

According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).

Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 4 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

L01XD04

L - Antineoplastic and immunomodulating agents

QL - Antineoplastic and immunomodulating agents

Protein BindingIn in vitro experiments using aminolevulinic acid (ALA) concentrations up to approximately 25% of the maximal concentration that occurs in plasma following the recommended dose of ALA solution, the mean protein binding of ALA was 12%.
Pharmacodynamics · 1 Eintrag

The metabolism of aminolevulinic acid (ALA) is the first step in the biochemical pathway resulting in heme synthesis. Aminolevulinic acid is not a photosensitizer, but rather a metabolic precursor of protoporphyrin IX (PpIX), which is a photosensitizer. The synthesis of ALA is normally tightly controlled by feedback inhibition of the enzyme, ALA synthetase, presumably by intracellular heme levels. ALA, when provided to the cell, bypasses this control point and results in the accumulation of PpIX, which is converted into heme by ferrochelatase through the addition of iron to the PpIX nucleus.

Mechanism of Action · 1 Eintrag

According to the presumed mechanism of action, photosensitization following application of aminolevulinic acid (ALA) topical solution occurs through the metabolic conversion of ALA to protoporphyrin IX (PpIX), which accumulates in the skin to which aminolevulinic acid has been applied. When exposed to light of appropriate wavelength and energy, the accumulated PpIX produces a photodynamic reaction, a cytotoxic process dependent upon the simultaneous presence of light and oxygen. The absorption of light results in an excited state of the porphyrin molecule, and subsequent spin transfer from PpIX to molecular oxygen generates singlet oxygen, which can further react to form superoxide and hydroxyl radicals. Photosensitization of actinic (solar) keratosis lesions using aminolevulinic acid, plus illumination with the BLU-UTM Blue Light Photodynamic Therapy Illuminator (BLU-U), is the basis for aminolevulinic acid photodynamic therapy (PDT).

Biological Half-Life · 1 Eintrag

The mean ± SD elimination half-life (t<sub>1/2</sub>) of aminolevulinic acid was 5.7 ± 3.9 hours for the topical solution formulation and the mean half-life was 0.9 ± 1.2 hours for the oral solution formulation. In another pharmacokinetic studies with 6 healthy volunteers using a 128 mg dose, the mean half-life was 0.70 ± 0.18 h after the oral dose and 0.83 ± 0.05 h after the intravenous dose.

Zugehörige Reaktionen

42
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 48004
HRID 48004als Edukt
Reaktionsgleichung von HRID 51096
HRID 51096als Edukt
Reaktionsgleichung von HRID 92480
HRID 92480als Edukt
Reaktionsgleichung von HRID 92793
HRID 92793als Edukt
Reaktionsgleichung von HRID 98801
HRID 98801als Edukt
Reaktionsgleichung von HRID 109314
HRID 109314als Edukt
Reaktionsgleichung von HRID 145772
HRID 145772als Edukt
Reaktionsgleichung von HRID 158708
HRID 158708als Edukt
ZurückSeite 1 von 6

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
DTXSID8048490
ChEMBL
CHEMBL601
ChEBI
CHEBI:17549
UNII
88755TAZ87
EC Number
203-414-1
Nikkaji
J38.537I
Schmelzpunkt
118 · 118-119 °C
Siedepunkt
242.42 °C · 242.42°C (rough estimate)
Dichte
1.3121 · 1.3121 (rough estimate)
Brechungsindex
1.43 · 1.4300 (estimate)
storage temp.
2 · 2-8°C(protect from light)
Löslichkeit
Soluble in DMSO
pka
4.05 · 4.05(at 25℃)
InChI
InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)
InChIKey
ZGXJTSGNIOSYLO-UHFFFAOYSA-N
SMILES
C(O)(=O)CCC(=O)CN
CAS Datenbank
106 · 106-60-5(CAS DataBase Reference)
EPA chemische Informationen
5 · Pentanoic acid, 5-amino-4-oxo- (106-60-5)

Aminolevulinic acid

DILI Positive

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Sicherheitsdaten

tsca
TSCA listed
hs_code
29225090
Metabolism/Metabolites · 2 Einträge

Exogenous aminolevulinic acid (ALA) is metabolized to PpIX, but the fraction of administered ALA that is metabolized to PpIX is unknown. The average plasma AUC of PpIX is less than 6% of that of ALA.

Following topical administration, synthesis into protoporphyrin IX takes place in situ in the skin. Half Life: Mean half-life is 0.70 &plusmn; 0.18 h after the oral dose and 0.83 &plusmn; 0.05 h after the intravenous dose.

FDA Pharmacological Classification · 6 Einträge

88755TAZ87

AMINOLEVULINIC ACID

Established Pharmacologic Class [EPC] - Porphyrin Precursor

Chemical Structure [CS] - Porphyrinogens

Established Pharmacologic Class [EPC] - Optical Imaging Agent

Mechanisms of Action [MoA] - Fluorescence Contrast Activity

MeSH Pharmacological Classification · 1 Eintrag

Drugs that are pharmacologically inactive but when exposed to ultraviolet radiation or sunlight are converted to their active metabolite to produce a beneficial reaction affecting the diseased tissue. These compounds can be administered topically or systemically and have been used therapeutically to treat psoriasis and various types of neoplasms.

Absorption, Distribution and Excretion · 3 Einträge

Oral bioavailability is 50-60%. ### **Topical gel** Pharmacokinetics (PK) of aminolevulinic acid (ALA) and PpIX was evaluated in a trial of 12 adult subjects with mild to moderate AK with at least 10 AK lesions on the face or forehead. A single dose of one entire tube of ALA (2 grams) was applied under occlusion for 3 hours followed by photodynamic therapy (PDT) to a total area of 20 cm2. The mean ± SD baseline plasma ALA and PpIX concentrations were 20.16 ± 16.53 ng/mL and 3.27 ± 2.40 ng/mL, respectively. In most subjects, an up to 2.5-fold increase of ALA plasma concentrations was observed during the first 3 hours after ALA application. The mean ± SD area under the concentration time curve (AUC0-t) and maximum concentration (Cmax) for baseline corrected ALA (n=12) were 142.83 ± 75.50 ng.h/mL and 27.19 ± 20.02 ng/mL, respectively. The median Tmax (time at which Cmax occurred) was 3 hours. ### **Topical solution** Two human pharmacokinetic (PK) studies were conducted in subjects with minimally to moderately thick actinic keratoses on the upper extremities, having at least 6 lesions on one upper extremity and at least 12 lesions on the other upper extremity. A single dose comprising of two topical applications of ALA topical solution (each containing 354 mg ALA HCl) were directly applied to the lesions and occluded for 3 hours prior to light treatment. The first PK study was conducted in 29 subjects and PK parameters of ALA were assessed. The baseline corrected mean ± SD of the maximum concentration (Cmax) of ALA was 249.9 ± 694.5 ng/mL and the median Tmax was 2 hours post dose. The mean ± SD exposure to ALA, as expressed by area under the concentration time curve (AUCt) was 669.9 ± 1610 ng·hr/mL. The mean ± SD elimination half-life (t1/2) of ALA was 5.7 ± 3.9 hours. A second PK study was conducted in 14 subjects and PK parameters of ALA and PpIX were measured. The baseline corrected PpIX concentrations were negative in at least 50% of samples in 50% (7/14) subjects and AUC could not be estimated reliably. The baseline-corrected mean ± SD of Cmax for ALA and PpIX was 95.6 ± 120.6 ng/mL and 0.95 ± 0.71 ng/mL, respectively. The median Tmax of ALA and PpIX was 2 hours post dose and 12 hours post dose, respectively. The mean AUCt of ALA was 261.1 ± 229.3 ng·hr/mL. The mean ± SD t1/2 of ALA was 8.5 ± 6.7 hours. ### **Oral solution** In 12 healthy subjects, the absolute bioavailability of ALA following the recommended dose of ALA solution was 100.0% + 1.1 with a range of 78.5% to 131.2%. Maximum ALA plasma concentrations were reached with a median of 0.8 hour (range 0.5 – 1.0 hour).

In 12 healthy subjects, excretion of parent aminolevulinic acid (ALA) in urine in the 12 hours following administration of the recommended dose of ALA solution was 34 + 8% (mean + std dev) with a range of 27% to 57%.

In healthy volunteers, the administration of aminolevulinic acid resulted in a volume of distribution of 9.3 ± 2.8 L intravenously and 14.5 ± 2.5 orally.[11961050]

Tissue LocationsBladder
Cellular LocationsMitochondria
Metabolite Pathways3-Phosphoglycerate dehydrogenase deficiency

Verwendung und Herstellung

UsesAminolevulinic acid plus blue light illumination using a blue light photodynamic therapy illuminator is indicated for the treatment of minimally to moderately thick actinic keratoses of the face or scalp.
General Manufacturing InformationPentanoic acid, 5-amino-4-oxo-: INACTIVE
Anwendungen · 2 Einträge

Beschreibung5-aminolevulinic acid is the simplest delta-amino acid in which the hydrogens at the gamma position are replaced by an oxo group. It is metabolised to protoporphyrin IX, a photoactive compound which accumulates in the skin. Used (in the form of the hydrochloride salt)in combination with blue light illumination for the treatment of minimally to moderately thick actinic keratosis of the face or scalp. It has a role as a photosensitizing agent, an antineoplastic agent, a dermatologic drug, a prodrug, a plant metabolite, a human metabolite, a Saccharomyces cerevisiae metabolite, an Escherichia coli metabolite and a mouse metabolite. It is a delta-amino acid and a 4-oxo monocarboxylic acid. It derives from a 4-oxopentanoic acid. It is a conjugate base of a 5-ammoniolevulinic acid. It is a conjugate acid of a 5-aminolevulinate. It is a tautomer of a 5-ammoniolevulinate.

Verwenden5-Aminolevulinic acid (ALA), a nonprotein amino acid involved in tetrapyrrole synthesis, has been widely applied in agriculture, medicine, and food production.5-Aminolevulinic acid (5-ALA) is an intermediate in heme biosynthesis and is useful in cancer treatment. It is a non-protein amino acid. 5-ALA also has applications in the field of agriculture. It is being studied as an inducing reagent for protoporphyrin IX (PPIX) dependent fluorescence diagnosis of metastatic lymph nodes. 5-ALA is used for photodynamic therapy of diseases, such as Paget′s disease and HPV infection-associated cervical condylomata acuminata.Intermediate in heme biosynthesis.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

Dinatrium-(3-oxo-6-oxido-2,4,5,7-tetraiod-3H-xanthen-9-yl)-3,4,5,6-tetrachlorbenzoatPalladiumdihydroxid

Nachgelagerte Produkte

Succinaldehydic acid2,5-PiperidinedioneTetramethyl-3,8,13,17-tetramethyl-21H,23H-porphin-2,7,12,18-tetrapropionatMethyl-5-amino-4-oxovalerathydrochlorid